Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR4 | Q13639 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2542098 | 1.00 | HTR4 (1.00) | HTR4 | |
| SCHEMBL30404126 | 1.00 | HTR4 (1.00) | HTR4 | |
| SCHEMBL29941552 | 1.00 | HTR4 (1.00) | HTR4 | |
| SCHEMBL393401 | 1.00 | HTR4 (1.00) | HTR4 | |
| Bromide SCHEMBL2538713 | 0.99 | HTR4 (0.98) | HTR4 | |
| Hydrochloric Acid SCHEMBL2541046 | 0.99 | HTR4 (0.98) | HTR4 | |
| SCHEMBL23093697 | 0.92 | HTR4 (0.86) | HTR4 | |
| SCHEMBL23093696 | 0.92 | HTR4 (0.86) | HTR4 | |
| SCHEMBL23093695 | 0.92 | HTR4 (0.86) | HTR4 | |
| SCHEMBL2540182 | 0.88 | HTR4 (0.79) | HTR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8044045-B2 | Indazole-carboxamide compounds as 5-HT4 receptor agonists | THERAVANCE, INC. (US) | 2011-10-25 | — | — | US | disclosed |
| US-20100261716-A1 | INDAZOLE-CARBOXAMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | THERAVANCE, INC. (US) | 2010-10-14 | — | — | US | disclosed |
| US-7674908-B2 | Indazole-carboxamide compounds as 5-HT4 receptor agonists | THERAVANCE, INC. (US) | 2010-03-09 | — | — | US | disclosed |
| US-7674908-B2 | Indazole-carboxamide compounds as 5-HT4 receptor agonists | THERAVANCE, INC. (US) | 2010-03-09 | — | — | US | disclosed |
| US-7674908-B2 | Indazole-carboxamide compounds as 5-HT4 receptor agonists | THERAVANCE, INC. (US) | 2010-03-09 | — | — | US | disclosed |
| US-20080146807-A1 | Indazole-carboxamide compounds as 5-HT4 receptor agonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2008-06-19 | — | — | US | disclosed |
| US-20080146807-A1 | Indazole-carboxamide compounds as 5-HT4 receptor agonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2008-06-19 | — | — | US | disclosed |
| US-20080146807-A1 | Indazole-carboxamide compounds as 5-HT4 receptor agonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2008-06-19 | — | — | US | disclosed |
| US-7351704-B2 | Indazole-carboxamide compounds as 5-HT4 receptor agonists | THERAVANCE, INC. (US) | 2008-04-01 | — | — | US | disclosed |
| US-7351704-B2 | Indazole-carboxamide compounds as 5-HT4 receptor agonists | THERAVANCE, INC. (US) | 2008-04-01 | — | — | US | disclosed |
| US-7351704-B2 | Indazole-carboxamide compounds as 5-HT4 receptor agonists | THERAVANCE, INC. (US) | 2008-04-01 | — | — | US | disclosed |
| US-20060183901-A1 | Crystalline form of an indazole-carboxamide compound | THERAVANCE, INC. | 2006-08-17 | — | — | US | disclosed |
| US-20050197335-A1 | 1-isopropyl-1H-indazole-3-carboxylic acid {(1S,3R,5R)-8-[2-(4-acetylpiperazin-1-yl)-ethyl]8-azabicyclo[3.2.1]oct-3-yl}amide; improved pharmacokinetic, bioavailability; gastrointestinal disorders: irritable bowel syndrome (IBS), chronic constipation, dyspepsia; CNS behavioral, mood disorder | THERAVANCE BIOPHARMA R&D IP, LLC | 2005-09-08 | — | — | US | disclosed |
| WO-2005080389-A1 | INDAZOLE-CARBOXAMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | THERAVANCE, INC. (US) | 2005-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050197335-A1 | 1-isopropyl-1H-indazole-3-carboxylic acid {(1S,3R,5R)-8-[2-(4-acetylpiperazin-1-yl)-ethyl]8-azabicyclo[3.2.1]oct-3-yl}amide; improved pharmacokinetic, bioavailability; gastrointestinal disorders: irritable bowel syndrome (IBS), chronic constipation, dyspepsia; CNS behavioral, mood disorder | HTR4, HTR5A, HTR3C | HTR4 1/4885 |
| US-20080146807-A1 | Indazole-carboxamide compounds as 5-HT4 receptor agonists | HTR4, HTR5A, HTR3B | HTR4 1/4885 |
| US-20060183901-A1 | Crystalline form of an indazole-carboxamide compound | HTR4, HTR3C, HTR5A | HTR4 1/4885 |
| US-20100261716-A1 | INDAZOLE-CARBOXAMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | HTR4, HTR5A, HTR3B | HTR4 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.